Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.

Weijun Gu et al.PubMed ↗Full text ↗Publisher ↗

A secondary analysis of NCT04251156. The trial’s primary report, PMID 38330988, speaks for it on the map; the numbers here are shown and do not vote.

Semaglutide 2.4 mglooks good hereLower body weight from baseline to Week 44, higher proportion of participants who achieved ≥5% reduction in body weight.Weak evidence: one subgroup.

What the trial testedrandomised · 2025

One subgroup

May have lowered body weight from baseline to Week 44 in Chinese participants

Doesn’t vote: a later paper about the trial

−8.30percentage points−10.2 to −6.40

semaglutide 2.4 mg vs placebo, in Chinese participants

As reported

difference −8.3 %, 95% CI −10.2 to −6.40 · the paper's word: change in mean body weight from baseline to Week 44

One subgroup

May have raised proportion of participants who achieved ≥5% reduction in body weight in Chinese participants

Doesn’t vote: a later paper about the trial

16×8.4× to 31×

semaglutide 2.4 mg vs placebo, in Chinese participants

Bigger than almost all on the map

As reported

OR 16.1, 95% CI 8.40–30.9 · the paper's word: proportion of participants who achieved ≥5% reduction in body weight from baseline

Who was studied, and how

375people in the Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity. trial, from 2020

of them with obesity, in this paper

Among Chinese participants, the trial randomly assignedassigned by chance

semaglutide 2.4 mg

placebo

May have lowered body weight from baseline to Week 44−8.30

May have raised proportion of participants who achieved ≥5% reduction in body weight16×

randomised · one subgroup

the abstract, start to end

… placebo (estimated treatment difference -8.3%; 95% confidence interval [CI] …

… placebo (85.4% vs. 26.8%): odds ratio 16.1; 95% CI 8.4, 30.9; p < 0.0001.

← favours treatmentfavours comparator →

could be chance

Change in mean body weight from baseline to Week 44semaglutide 2.4 mg vs placebo, in Chinese participants

−8.3−10.2 to −6.40

Proportion of participants who achieved ≥5% reduction in body weight from baselinesemaglutide 2.4 mg vs placebo, in Chinese participants

OR 16.18.40–30.9

GLP-1 receptor agonistsBody weight & composition

1 / 4

4 papers cite it

2025

2026

this paperpooled ittrialcites it

The trial

NCT04251156phase 3375 enrolled2020a later paper about it